================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                          ----------------------------


                                    FORM 8-K

                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

        Date of report (Date of earliest event reported): August 8, 2007

                           Critical Therapeutics, Inc.
               (Exact Name of Registrant as Specified in Charter)

             Delaware                  000-50767            04-3523569
   (State or Other Jurisdiction       (Commission         (IRS Employer
         of Incorporation)            File Number)      Identification No.)


  60 Westview Street, Lexington, Massachusetts                   02421
    (Address of Principal Executive Offices)                   (Zip Code)

       Registrant's telephone number, including area code: (781) 402-5700

                                 Not applicable
          (Former Name or Former Address, if Changed Since Last Report)

         Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))


================================================================================



Item  2.02.     Results of Operations and Financial Condition.

On August 8, 2007, Critical Therapeutics, Inc. (the "Company") announced its
financial results for the quarter ended June 30, 2007. The Company also provided
guidance regarding anticipated net cash expenditures for the year and six months
ended December 31, 2007. The full text of the press release issued in connection
with the announcement is attached as Exhibit 99.1 to this Current Report on Form
8-K.

The information in this Form 8-K and Exhibit 99.1 attached hereto shall be
deemed incorporated by reference in any registration statement previously or
subsequently filed by the Company under the Securities Act of 1933, as amended,
except to the extent that such information is superseded by information as of a
subsequent date that is included or incorporated by reference into such
registration statement.



Item 9.01.      Financial Statements and Exhibits.

         (d)      Exhibits.

                  See Exhibit Index attached hereto.



                                    SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:  August 8, 2007                CRITICAL THERAPEUTICS, INC.

                                     By:  /s/ Frank E. Thomas
                                          --------------------------------------
                                          Frank E. Thomas
                                          President and Chief Executive Officer



                                  EXHIBIT INDEX

Exhibit No.                 Description
-----------                 ----------------------------------------------------

99.1                        Press release dated August 8, 2007.